OncoZenge (ONCOZ.ST) Stock Analysis & AI Equity Report
OncoZenge (ONCOZ.ST) overview
OncoZenge (ONCOZ.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, OncoZenge reported revenue of SEK 2.7m and operating profit of SEK -15.9m; the year-end share price was 6.76 SEK and market capitalisation was SEK 82.0m. OncoZenge is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get OncoZenge's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-05-21. Data will be refreshed during report generation.
About OncoZenge
OncoZenge AB is a clinical-stage pharmaceutical company based in Stockholm that develops BupiZenge, an oral lozenge formulation of bupivacaine for oral pain. Its lead focus is oral mucositis linked to cancer therapy, with the aim of providing local pain relief where current treatments are limited or carry significant side effects.
Generate the OncoZenge report
OncoZenge is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for OncoZenge and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.